Interim data from Aptevo Therapeutics Inc.'s ongoing RAINIER clinical trial shows that the company's investigational therapy mipletamig, when combined with standard-of-care venetoclax and azacitidine, delivered an 86% clinical benefit rate in newly diagnosed acute myeloid leukemia patients. This includes a 79% remission rate, with 55% of those achieving remission reaching MRD-negative status, meaning highly sensitive tests could not detect any remaining leukemia cells.
The emerging data suggest mipletamig may enhance the current frontline AML treatment approach, particularly for older patients or those with other health conditions who cannot tolerate intensive chemotherapy. For these patients, treatment options are limited and outcomes remain poor, making the development of tolerable therapies that improve clinical benefit compared to current regimens potentially redefining for AML care. The therapy's safety profile is equally notable, with no patients treated to date experiencing cytokine release syndrome, a common and potentially serious immune reaction that can force patients to discontinue therapy.
Mipletamig is a bispecific antibody designed to target CD123, a marker commonly found on AML leukemia cells, while simultaneously connecting with T-cells, the immune system's natural cancer fighters. This targeted approach activates the immune response against AML while maintaining a safety profile that allows combination with existing frontline treatments. The RAINIER trial, a phase 1b dose optimization study, is evaluating mipletamig in combination with venetoclax and azacitidine in patients newly diagnosed with AML who are older or unable to receive intensive chemotherapy.
Acute myeloid leukemia affects approximately 22,000 people in the United States annually and remains one of the most aggressive adult leukemias. Marvin White, President and Chief Executive Officer of Aptevo Therapeutics, stated that the frontline data show mipletamig has the potential to play a meaningful role in future frontline AML treatment, citing strong remission outcomes together with the continued absence of cytokine release syndrome as an encouraging combination of efficacy and safety. The company's research represents progress toward therapeutic advances that improve outcomes without adding significant toxicity for patients with limited treatment options. Further information about the company and its research can be found at https://www.aptevotherapeutics.com.
